To date, no studies conducted in the Middle East have reported on the outcomes of GLP-1 receptor agonists in the treatment of obesity, both with and without diabetes, in children and adolescents. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.